Navigation Links
China Sky One Medical, Inc. Acquires Heilongjiang Haina Pharmaceutical Inc.
Date:4/24/2008

HARBIN, China, April 24 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (OTC Bulletin Board: CSKI), a pharmaceutical company for external use over-the-counter drugs in the People's Republic of China ("PRC"), today announced it acquired Heilongjiang Haina Pharmaceutical Inc. ("Haina Pharmaceutical"), a recently formed corporation organized under the laws of the PRC on April 18, 2008.

China Sky One Medical, Inc., through its indirect wholly owned subsidiary Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), consummated a transaction pursuant to an Equity Transfer Agreement with Heilongjiang Haina Pharmaceutical Inc., licensed as a wholesaler of traditional Chinese medicine, bio-medicines, bio-products, medicinal devices, antibiotics and chemical medicines.

Pursuant to the Equity Transfer Agreement, Harbin acquired 100% of the issued and outstanding capital stock of Haina Pharmaceutical from its three stockholders in consideration for payment of 3,000,000 RMB (approximately $428,571). TDR has been overseeing the operations of Haina Pharmaceutical since January 2008 as part of its due diligence prior to closing of this acquisition.

Haina Pharmaceutical does not have an established sales network and was acquired for its primary asset, a Good Supply Practice (GSP) license issued as of December 21, 2006 by the Heilongjiang office of the SFDA, and will expire on January 29, 2012. The SFDA recently started issuing such licenses to resellers of medicines in order to maintain certain quality controls. The GSP license enables China Sky One Medical to expand its sales of medicinal products without having to go through a lengthy license application process.

"We are pleased to complete the acquisition of Haina Pharmaceutical. By obtaining the GSP license, we now have the ability to further develop our sales channels in a timely manner," said Mr. Yan-qing Liu, Chairman, CEO and Director of China Sky One Medical, Inc.

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR") and Harbin First Bio- Engineering Company Limited ("First"), the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

For more information, please contact:

China Sky One Medical, Inc.

Ms. Xiaoyan Han, CFO

Tel: +86-1335-999-3681

Email: tdrhan@163.com

CCG Elite Investor Relations Inc.

Mr. Crocker Coulson, President

Tel: +1-646-213-1915 (New York)

Email: crocker.coulson@ccgir.com


'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Syngenta To Build Major Global Biotech Research Center in Beijing, China
2. American Oriental Bioengineering and China Aoxing Pharmaceutical Enter Into Strategic Alliance
3. China YCT International Group, Inc. Announces Entrusted Management Agreement With Its Primary Supplier
4. CTDC Attends the Inauguration Ceremony of Thin Film A-Si Manufacturing Line in Changzhou, China
5. China Bio Energy Reports Fiscal 2007 Financial Results
6. Transgenomic Opens Pharmacogenomics Laboratory in China
7. China Pharma Holdings, Inc. Announces Record 2007 Year End Results
8. China Kangtai Cactus Biotech, Inc. Obtains $500,000 Equity Financing
9. Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the Peoples Republic of China
10. Aida Acquires High-Level Research Institute in China
11. China Pharma Holdings, Inc. Announces Earnings Call for Fiscal 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... ... Franz Inc ., the leading supplier of Semantic Graph Database technology, today ... Bloor Research in its recent Graph Database Market Update report. ... it was rated as the easiest product to use.” – Bloor Research , ...
(Date:3/28/2017)... and WASHINGTON , March 28, 2017 ... GENEWIZ, will launch single-cell sequencing during the American Association for ... Washington Convention Center in Washington, D.C. ... perform differential gene expression of thousands of cells at ... Experts on-hand at AACR to ...
(Date:3/28/2017)... , March 28, 2017 Biostage, Inc. ... company developing bioengineered organ implants to treat cancers and ... today announced that Jim McGorry, CEO of ... BioEngineering panel at the MassBio 2017 Annual ... PM ET in Cambrige, Massachussetts. The 3D Printing ...
(Date:3/28/2017)... /PRNewswire/ -RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ... and clinical data from its phase 1/2 tendon repair study ... fibroblasts (RCT-01) as a treatment for Achilles tendinosis. ... The clinical ... at 6 months and showed no serious adverse events related ...
Breaking Biology Technology:
(Date:3/2/2017)... Australian stem cell and regenerative medicine company, ... an agreement with the Monash Lung Biology Network, a ... and Department of Pharmacology at Monash University, ... to support the use of Cymerus™ mesenchymal stem cells ... Asthma is a chronic, long term lung condition recognised ...
(Date:2/28/2017)... BARCELONA , Spanien, 27. Februar 2017 /PRNewswire/ ... durch Iris-Scan, wird seine erstklassige biometrische Lösung ... Snapdragon™ 835 mit X16 LTE auf dem ... 2. März) am Qualcomm-Stand in Halle 3, ... 835-Prozessor beinhaltet die Sicherheitsplattform Qualcomm Haven™ – ...
(Date:2/22/2017)... , Feb. 22, 2017 With ... 2021, ABI Research identifies four technologies that innovative ... to secure significant share in the changing competitive ... and passive authentication.   "Companies can ... comes to security," says Dimitrios Pavlakis , ...
Breaking Biology News(10 mins):